This year’s conference pin by AMERSA member, Claire Zagorski, MSc, LP can be purchased at the registration desk.
THANK YOU TO OUR SPONSORS AND EXHIBITORS!

Sponsors

Thank you to NIDA CTN for sponsoring the 2023 Growing a Diverse Workforce Award recipients.

Thank you to Substance Use & Addiction Journal for sponsoring this year’s conference lanyards.

Exhibitors

Thank you to NIDA CTN for sponsoring the 2023 Growing a Diverse Workforce Award recipients.

Thank you to Substance Use & Addiction Journal for sponsoring this year’s conference lanyards.

Exhibitors
AMERSA seeks to create an open and welcoming environment at our conferences and other gatherings, whether in-person or virtual. AMERSA has pledged to promote cultural, linguistic, and racial equity and inclusion as we advance evidence-based and interprofessional substance use scholarship, policies, and clinical practice. That commitment extends to creating a safe space for all AMERSA events in which there is no discrimination based on gender identity, sexuality, physical appearance, race, disability, age, socioeconomic position, or political leanings. Below are code of conduct policies regarding person-first language, alcohol consumption at AMERSA events, photography, suggestions for positive behaviors and reporting harassment. This code of conduct applies to all convening participants and all event-related staff (e.g. hotel staff, AV technicians, interpreters, etc.). It applies to all convening-related activities such as sessions related to the formal agenda; all related side- and social- events; parties; and informal gatherings at restaurants or bars.

Person-first language
AMERSA is a leader in promoting person-first language and avoiding terminology that can be stigmatizing. Specifically, person-first language (1) respects the worth and dignity of all persons and avoids perpetuating negative stereotypes and biases through the use of slang and idioms. Conference attendees are asked to follow the principles outlined in the publication cited below, accessible at https://pubmed.ncbi.nlm.nih.gov/24911031/. Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus. 2014;35(3):217-221. Doi:10.1080/08897077.2014.930372 When speaking about patients or persons who use substances, it is important to be respectful of the persons who are the focus of the discussion, maintaining anonymity of the person(s) as well as being acutely aware that persons with such lived experiences may be in the audience.

Alcohol
AMERSA does not provide alcohol for sponsored events, including the annual conference, and prohibits the use of AMERSA funds for purchase or provision of alcoholic beverages at any gatherings of the association.

Positive Behaviors
For real discussions to take place, it is inevitable to have different expressions and opinions, however, any kind of harassment will not be tolerated. In the case of any harassment, we will take strict action, as outlined in the Enforcement section below. To build a conductive atmosphere, we provide the following examples of positive behaviors. • Recognize the value of scholarly disagreements and convey respect for the opinions of others; • When speaking, briefly introduce yourself: provide your name and your affiliation; • In the question period following a presentation, be succinct; please restrict yourself to one question or one comment; • Be audible and speak with clarity; • Be an active and engaged listener when someone is expressing themselves; • Maintain your calm, address the issue; • Disagreements happen; it’s okay to walk away from a conversation that isn’t fruitful or is becoming tense; • Do not assume anyone’s gender identity, gender pronouns (some people don’t identify with the sex they were assigned at birth, and others use gender-neutral pronouns. You can ask people what their gender pronoun is), sexual orientation, survivor status, economic status, background, or health status; • Try to refer to people by their name.

Reporting Harassment
If you are being harassed or observe someone being harassed, please report by taking the following actions. • Locating an AMERSA staff at the registration desk; • Communicating with the AMERSA host of the virtual event; • Emailing the AMERSA Executive Director or AMERSA host of the event. All reports made will be kept confidential except when otherwise prohibited by law (there is a threat to self or others or a serious crime has been committed).

Photography
Please ask permission beforehand to determine the individual’s comfort level with being photographed.

Enforcement
AMERSA staff and leaders may intervene when there is a concern of code of conduct. Participants who are asked to stop any behavior inconsistent with the code of conduct are expected to remediate their behavior and follow the request. All complaints will be reviewed and investigated and will result in a response that is deemed necessary and appropriate to the circumstances. Event organizers retain the right to take any action to keep the event a welcoming environment for all participants. This includes warning the offender, expulsion from the conference/ event, mediation with the complainant / victim in the complaint and the person alleged to have participated in harassing or discriminatory behavior. However, to preserve both the safety and the confidentiality of the complainant / victim in the complaint, no specific action will be taken without consultation and their approval. Any illegal conduct will also be reported to local authorities if needed.
AMERSA’s Mission

AMERSA (Association for Multidisciplinary Education and Research in Substance use and Addiction), founded in 1976, is a non-profit, professional organization whose mission is to improve health and well-being through interdisciplinary leadership and advocacy in substance use education, research, clinical care and policy.

AMERSA Program Planning Committee

Planning Committee Co-Chairs
Kristin Wason, MSN, AGPCNP-BC, CARN
Richard Bottner, DHA, PA-C, CPHQ, FACHE
Jeffrey P. Bratberg, PharmD, FAPhA
Deborah S. Finnell, DNS, RN, CARN-AP, FAAN
Adrienne Galloway, MBA
Adam Gordon, MD, MPH
Holly N. Hagle, PhD

Abstract Committee Co-Chairs
Tae Woo (Ted) Park, MD, MSc
Raagini Jawa, MD

Conference Travel Award Co-Chairs
Avik Chatterjee, MD, MPH
Chin Hwa (Gina) Y. Dahlem, PhD, FNP-C, FAANP

Workshop Chair
Paula J. Lum, MD, MPH

Mentorship Chair
Ximena A. Levander, MD, MCR

Program Planning Committee Members
Nicolas Bertholet, MD, MSc
Richard Bottner, DHA, PA-C, CPHQ, FACHE
Jeffrey P. Bratberg, PharmD, FAPhA
Deborah S. Finnell, DNS, RN, CARN-AP, FAAN
Adrienne Galloway, MBA
Adam Gordon, MD, MPH
Holly N. Hagle, PhD
Miriam Komaromy, MD
Marlene Martin, MD
Shannon Mountain-Ray, MSW, LICSW
Rebecca Northup, MA
Shannon Smith-Bernardin, PhD, RN, CRL
Zoe Weinstein, MD, MS
Rachel Winograd, PhD

Board of Directors 2023-2024

President: Deborah S. Finnell, DNS, RN, CARN-AP, FAAN
President Elect: Miriam Komaromy, MD
Secretary: Shannon Smith-Bernardin, PhD, RN, CRL
Treasurer: Holly N. Hagle, PhD
Editor-in-Chief, SAj: Adam Gordon, MD, MPH
Member-at-Large: Nicolas Bertholet, MD, MSc
Member-at-Large: Richard Bottner, DHA, PA-C, CPHQ, FACHE
Member-at-Large: Lucas Hill, PharmD, BCACP
Member-at-Large: Shannon Mountain-Ray, MSW, LICSW
Member-at-Large: Tae Woo Park, MD, MSc
Member-at-Large: Leslie W. Suen, MD, MAS
Member-at-Large: Kristin Wason, MSN, AGPCNP-BC, CARN
AMERSA Executive Director: Rebecca Northup, MA
AMERSA Associate Director: Adrienne Galloway, MBA
At the conclusion of this educational activity, participants should be able to:

• Utilize newly obtained knowledge and skills in teaching, clinical, research, advocacy, and/or community-based approaches.
• Describe existing research, research gaps, and innovative approaches to improving research, clinical, and community-based practice around substance use and addiction.
• Identify substance use-related policy and apply it to teaching, clinical, research, and/or community-based opportunities.
• Identify mentoring opportunities to expand clinical, teaching, research, and/or community-based opportunities.
• Recognize the benefit of interdisciplinary collaboration and identify strategies to leverage interdisciplinary experience and training, to improve teaching, clinical, research, and/or community-based opportunities.
• Identify and address the impact of diversity, equity, and inclusion (DEI) considerations in teaching, clinical, research, and/or community-based practices.

All attendees are invited to nominate topics and speakers for next year’s conference program. During this year’s conference, plan to join us for the program planning breakfast on Saturday morning to discuss and recommend engaging speakers, cutting edge topics, or thorny dilemmas you’ve encountered while working in the field of addiction science.

After the conference, suggestions can still be sent to the 2024 Program Co-Chair, Megan Buresh, MD at mburesh2@jhmi.edu before November 30th for consideration.
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit for this activity is designated for learners in the following ways:

**Physician Designation Statement**
American Academy of Addiction Psychiatry designates this live activity for a maximum of 17.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nursing Designation Statement**
American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP's Joint Accreditation provider #4008192. This activity is approved for up to 17.75 CNE credits.

**Pharmacy Designation Statement**
This activity has been approved for 17.75 hours of pharmacy continuing education credit. The approval number issued is Universal Activity Number: UAN JA4008192-9999-23-033-L01-P (pharmacy) and UAN JA4008192-9999-23-033-L01-T (pharmtech.)

**AAPA Credit Designation Statement**
American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 17.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

**Social Work Designation Statement**
As a Jointly Accredited Organization, American Academy of Addiction Psychiatry (AAAP) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. AAAP maintains responsibility for this course. Social workers completing this course receive 17.75 continuing education credits.

**Psychologist Designation Statement**
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity is approved for 17.75 CE credits.

**IPCE Designation Statement**
This activity was planned by and for the healthcare team, and learners will receive 17.75 Interprofessional Continuing Education credits for learning and change.

**Other Health Professionals**
This activity was designated for 17.75 AMA PRA Category 1 Credits™. This credit is accepted by the AANP and the AAPA.
AMERSA Conference Agenda

Tuesday, October 31st, 2023

12:00 pm - 6:00 pm   Conference Registration
GEORGE WASHINGTON BOARDROOM

Wednesday, November 1st, 2023

7:00 am - 7:00 pm   Conference Registration
GRAND FOYER EAST

8:00 am - 4:00 pm   AMERSA Board of Directors Meeting
RENWICK

1:00 pm - 4:00 pm   Advocacy Training Workshop “Becoming an Effective Drug Policy Reform Advocate” led by Jules Netherland, MSW, PhD and Sheila P. Vakharia, PhD, MSW of Drug Policy Alliance.
PENN AB

4:00 pm - 4:30 pm   Refreshment Break
PENN AB HALL

4:30 pm - 5:45 pm   The More Things Change, the More Things Stay the Same: Marie Nyswander and the History of Methadone in the U.S. led by Amy Scharf, PhD, Executive Producer of Lost Women of Science podcast. This exciting fireside chat style panel on Marie Nyswander and the history of methadone will feature members of the Lost Women of Science podcast team, historian Emily Dufton, MD, and addiction medicine physician, Soraya Azari, MD. Moderated by Megan Buresh, MD.
PENN AB

7:00 pm - 8:00 pm   Recovery Meeting
CABINET RESTAURANT

Jules Netherland, MSW, PhD

Sheila P. Vakharia, PhD, MSW

Amy Scharf, PhD

Emily Dufton, MD

Soraya Azari, MD

Megan Buresh, MD, DFASAM
AMERSA Conference Agenda

Thursday, November 2nd, 2023

6:00 am                   Fun Run/Walk
MEET IN LOBBY

7:00 am - 7:00 pm   Conference Registration
CONSTITUTION FOYER

7:00 am - 8:30 am   Networking Breakfast Buffet
CONSTITUTION FOYER

7:00 am - 8:15 am   Past Presidents’ Breakfast
RENWICK

8:30 am - 9:00 am   President’s Welcome
CONSTITUTION BALLROOM

9:00 am - 10:00 am   Opening Plenary—How to Effectively Advocate to Create Change
CONSTITUTION BALLROOM

9:00 am - 10:00 am   Opening Plenary—How to Effectively Advocate to Create Change
led by authors of the newly released book “Whiteout: How Racial Capitalism Changed the Color of Opioids in America”, Jules Netherland, MSW, PhD, Managing Director of Research and Academic Engagement, Drug Policy Alliance and Helena Hansen, MD, PhD, Professor and Interim Chair, Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA; Interim Director, Semel Institute for Neuroscience and Human Behavior. Moderated by Sheila P. Vakharia PhD, MSW, Deputy Director, Department of Research and Academic Engagement, Drug Policy Alliance.

10:00 am - 10:30 am   Refreshment Break
CONSTITUTION FOYER

10:30 am - 11:45 am   Local Hot Topics Plenary—Innovative Programs to Expand Access to MOUD in Rural Maryland
CONSTITUTION BALLROOM

10:30 am - 11:45 am   Local Hot Topics Plenary—Innovative Programs to Expand Access to MOUD in Rural Maryland
led by Eric Weintraub, MD, Professor of Psychiatry, Director, Division of Addiction, Research and Treatment, University of Maryland, School of Medicine; Alicia Lebon, Sr Community Outreach Specialist for the Support to Restore at The John Hopkins University School of Medicine Division of Infectious Diseases; Roger McKnight, Caroline County MD, Behavioral Health, Mobile Treatment Unit Administrator, Peer Recovery Specialist/CERTIFIED, Registered Peer Supervisor. Moderated by Tracy Agee, NP, Senior Nurse Practitioner, Director RESTORE+, The Johns Hopkins Center for Substance Use and Infectious Disease Care Integration

Jules Netherland, MSW, PhD
Helena Hansen, MD, PhD
Sheila P. Vakharia, PhD, MSW

Eric Weintraub, MD
Alicia Lebon
Roger McKnight
Tracy Agee, NP
AMERSA Conference Agenda

Thursday, November 2, 2023

12:00 pm - 1:30 pm  Lunch on Your Own

12:00 pm - 1:30 pm  Growing a Diverse Workforce Awardee Lunch

1:30 pm - 2:45 pm  Oral Abstract Presentation Session 1

SEE PAGES 13-16 FOR INFORMATION

2:45 pm - 3:00 pm  Break

5:15 pm - 5:45 pm  New Member and 1st Time Attendee Q&A Forum

Friday, November 3rd, 2023

5:45 am  Fun Run/Walk with Back on My Feet

MEET IN LOBBY

7:00 am - 7:00 pm  Conference Registration

CONSTITUTION FOYER

7:00 am - 8:15 am  SIG Breakfast Meetings & Networking Breakfast Buffet

CONSTITUTION FOYER AND PENN AB HALL (FOR NURSING SIG)
AMERSA Conference Agenda

8:30 am - 9:45 am  Fetal Alcohol Spectrum Disorders (FASDs) Plenary: Common, Complex and Unrecognized led by Kendra Gludt, MPH, Director of National Programs, Proof Alliance; Vincent C. Smith, MD, MPH, Division Chief of Newborn Medicine, Boston Medical Center, Professor of Pediatrics, Boston University Chobanian & Avedisian School of Medicine; Sue Terwey, MS, Psychiatric Associate, Adolescent Mental Health, Masonic Children’s Hospital, M Health Fairview; Jeffrey Wozniak, PhD, Professor, Department of Psychiatry & Behavioral Sciences, Director for Child & Adolescent Mental Health Research, University of Minnesota. Moderated by Daniel P. Alford, MD, MPH, Professor of Medicine, Director, Clinical Addiction Research and Education (CARE) Unit; Associate Dean, Barry M. Manuel Center for Continuing Education, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center

9:45 am - 10:00 am  Break

10:00 am - 11:30 am  AMERSA Discourse: Methadone Deregulation led by Denis Antoine III, MD, Director, Addiction Treatment Services Clinic, Johns Hopkins Bayview Medical Center; Ruth A. Potee, MD, FASAM, Medical Director, Franklin County House of Corrections; Director of Addiction Services, Behavioral Health Network. Moderated by Michelle Geier, PharmD, BCPP, APH, San Francisco Department of Public Health Behavioral Health Services, Psychiatric Clinical Pharmacist Supervisor

11:30 am - 1:15 pm  AMERSA Recognition Awards Luncheon or Lunch on Own

CONSTITUTION BALLROOM CDE: MUST PRESENT TICKET AT ENTRY

Kendra Gludt, MPH  Vincent C. Smith, MD, MPH  Sue Terwey, MS  Jeffrey Wozniak, PhD  Daniel P. Alford, MD, MPH  Denis Antoine III, MD  Ruth A. Potee, MD, FASAM  Michelle Geier, PharmD, BCPP, APH
Native Health Plenary: Advocating for Culturally Centered Evidence-based Treatments with Native Americans led by Loretta Christensen, MD, MBA, MSJ, FACS, Chief Medical Officer, Indian Health Service; Maria Christina Crouch (Deg Hit’an & Coahuiltecan), PhD, Postdoctoral Fellow, Yale School of Medicine, Department of Psychiatry; Kamilla Venner, PhD, Associate Professor, Center on Alcohol, Substance use, & Addiction (CASAA)

1:30 pm - 2:45 pm  CONSTITUTION BALLROOM

2:45 pm - 3:15 pm  Refreshment Break  CONSTITUTION FOYER

3:15 pm - 4:45 pm  Skills Based Workshops  SEE PAGES 17-18 FOR INFORMATION

5:00 pm - 7:00 pm  Networking  CONSTITUTION FOYER

5:00 pm - 5:30 pm  Advocacy Task Force Meet and Greet  CONSTITUTION CDE

5:45 pm - 6:15 pm  SAj Meet and Greet  CONSTITUTION CDE

6:30 pm - 7:00 pm  Diversity Committee Meet and Greet  CONSTITUTION CDE

7:15 pm - 8:15  Recovery Meeting  CABINET RESTAURANT
AMERSA Conference Agenda

Saturday, November 4th, 2023

6:30 am Fun Run/Walk

7:30 am Registration Desk Opens

7:30 am - 9:15 am Breakfast Buffet

8:00 am - 9:15 am Program Planning Breakfast

9:30 am - 11:00 am Rich Saitz’ “What’s the Evidence Really?” Endowed Plenary: Stimulant Use Disorder – Emerging Pharmacotherapies, Behavioral Therapies and Harm Reduction led by Joy Chudzynski, PsyD, Director, Substance Management Program for UCLA Athletics, Center for Behavioral & Addiction Medicine, UCLA Department of Family Medicine; Stephen P. Murray, MPH, NRP, Director, Massachusetts Overdose Prevention Helpline and Harm Reduction Program Manager, Boston Medical Center, Clinical Addiction Research & Education Unit; Steven Shoptaw, PhD, Professor and Vice Chair for Research, UCLA Department of Family Medicine; Daryl Shorter, MD, Associate Professor at Baylor College of Medicine; Medical Director of Addictions Services at The Menninger Clinic. Moderated by Justin Alves MSN, FNP-BC, ACRN, CARN, CNE, Addiction Nurse Educator, Grayken Center for Addiction Training and Technical Assistance...

11:00 am - 11:15 am Break
11:15 am - 12:30 pm  **Plenary Session: Best Abstract Presentations and Presentation of Abstracts Awards**  
**Introductions by: Tae Woo Park, MD, MSc**

**Best Research Abstract Award Presentation:** Bridging to Better Substance Use Treatment: Implementation and Effectiveness of Statewide Emergency Department Opioid Use Disorder Treatment Programs in California. Presented by: **Elizabeth A. Samuels, MD, MHS, MPH;** UCLA Department of Emergency Medicine, CA Bridge

**Best Research Abstract Award-Runner-up Presentation:** Patient Navigation for Pregnant Persons with Opioid Use Disorder: Results of a Multisite Pilot Study. Presented by: **Gerald Cochran, PhD, MSW;** University of Utah School of Medicine

**The John Nelson Chappel Best Curriculum, Quality Improvement, and Program Abstract Award Presentation:** Xylazine in the Illicit Drug Supply- Need for Responsive Educational Models. Presented by: **Raagini Jawa, FASAM, MD, MPH 1, Stephen P. Murray, MPH, NRP 2;** (1) University of Pittsburgh School of Medicine, (2) Boston Medical Center;

**The John Nelson Chappel Best Curriculum, Quality Improvement, and Program Abstract Award-Runner-up Presentation:** Utilizing the First Sanctioned Overdose Prevention Center to Provide Directly-Observed HCV Treatment Among People Who Inject Drugs in NYC. Presented by: **Brianna L Norton, DO, MPH;** Montefiore Medical Center/Albert Einstein College of Medicine

12:30 pm - 2:00 pm  **Grab-and-Go Sandwich Lunch Break & Mentor/Mentee Meetings**

**CONSTITUTION CDE:** **MUST PRESENT TICKET FOR BOXED LUNCH**

2:00 pm - 3:45 pm  **Oral Abstract Presentations: Session 2**

**SEE PAGES 19-23 FOR INFORMATION**

4:00 pm - 4:30 pm  **Annual Business Meeting**

**CONSTITUTION CDE**

4:30 pm  **Adjourn**
### Session 1.1 • Infectious Diseases
**Room: Penn B**

**Moderator:** Philip Todd Korthuis, MD, MPH

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Exploring Sexualized Drug Use, Sexual Behaviors, and Substance Use Among Sexual and Gender Diverse People in California</td>
<td>Daryl A. Mangosing, BA, MPH, DrPH; University of California Berkeley</td>
<td></td>
</tr>
<tr>
<td>3:17 pm</td>
<td><strong>HIV Pre- and Post-Exposure Prophylaxis Prescribing for Hospitalized People Who Inject Drugs Cared for by an Addiction Consult Service</strong></td>
<td>Paul J. Christine, MD, PhD; Boston Medical Center</td>
<td></td>
</tr>
<tr>
<td>3:34 pm</td>
<td><strong>Endocarditis from Injection Drug Use: A Preliminary Review of the Impact of Multidisciplinary Collaboration</strong></td>
<td>Alexander H. Hu; Boston University Chobanian &amp; Avedisian School of Medicine</td>
<td></td>
</tr>
<tr>
<td>3:51 pm</td>
<td>Co-Delivery of HIV Pre-Exposure Prophylaxis (PrEP) and HIV testing Among Publicly Insured Adolescents and Young Adults (AYA) Receiving Medication for Opioid Use Disorder (M OUD)</td>
<td>Maria Christina Herrera, MD, MSHP; Children's Hospital of Philadelphia</td>
<td></td>
</tr>
<tr>
<td>4:08 pm</td>
<td>Peer-Facilitated Telemedicine Hepatitis C Treatment for Rural People Who Use Drugs: Results from a Randomized Controlled Trial</td>
<td>Philip Todd Korthuis, MD, MPH, Hunter C. Spencer, DO; Oregon Health &amp; Science University</td>
<td></td>
</tr>
</tbody>
</table>

### Session 1.2 • Education #1
**Room: Latrobe**

**Moderator:** Alyssa Falleni, PharmD, RPh

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Emergency Medicine Resident Experiences, Perceptions, and Beliefs Regarding Medications for the Treatment of Alcohol Use Disorder</td>
<td>Joshua Reed Bia, MD; Yale</td>
<td></td>
</tr>
<tr>
<td>3:17 pm</td>
<td>Evaluation of a Curriculum on Medication for Opioid Use Disorder for Emergency Medicine Residents</td>
<td>Erin Kim, MD Candidate; University of Michigan</td>
<td></td>
</tr>
<tr>
<td>3:34 pm</td>
<td>Impact of a Medication for Opioid Use Disorder Curriculum for Emergency Medicine Residents</td>
<td>Erin Kim, MD Candidate; University of Michigan</td>
<td></td>
</tr>
<tr>
<td>3:51 pm</td>
<td>A Case-Based Curriculum to Enhance Attitude, Competency, and Knowledge of Buprenorphine for Treatment of Opioid Use Disorder Among Internal Medicine Residents</td>
<td>Sebastian Suarez, MD, MPH; Boston University Medical Center</td>
<td></td>
</tr>
<tr>
<td>4:08 pm</td>
<td>A Stigma-Disrupting Core Curriculum Influenced Internal Medicine Residents’ Regard for Patients with Substance Use Disorders</td>
<td>Katharine F. Marshall, MD; Northwest Permanente, P.C.</td>
<td></td>
</tr>
<tr>
<td>4:25 pm</td>
<td>Development of an Ambulatory Addiction Medicine Curricula for Internal Medicine (IM) Residencies at Two Veterans Affairs (VA) Facilities</td>
<td>Alyssa Falleni, PharmD, RPh 1, 2, Cynthia Frary Mcnamara, MD 2, 3, 4, Amy J. Kennedy, MD, MS 5; (1) VA Connecticut Healthcare System, (2) Yale School of Medicine, (3) VACT Healthcare System, (4) VA Connecticut Healthcare System, Yale School of Medicine, (5) VA Puget Sound Healthcare System</td>
<td></td>
</tr>
</tbody>
</table>
### Session 1.3 • MOUD #1
**Room: Penn A**
**Moderator: Rachel Winograd, PhD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Applying a Care Continuum Framework for Opioid Use Disorder in New York State: a Longitudinal Cohort Analysis</td>
<td>Chinazo Cunningham, MD, MS, Ashly E. Jordan, MPH, PhD; New York State Office of Addiction Services and Supports</td>
</tr>
<tr>
<td>3:17 pm</td>
<td>The First Five Years of Missouri’s Medication First Approach to Opioid Use Disorder Treatment: Plateaus, Regressions, and the Underbelly of Progress</td>
<td>Rachel Winograd, PhD; University of Missouri-Saint Louis</td>
</tr>
<tr>
<td>3:34 pm</td>
<td>Mental Health Distress is Associated with Higher Pain Interference in Patients Treated with Medications for Opioid Use Disorder</td>
<td>Sarah Leyde, MD, Joseph O Merrill, MD, MPH; University of Washington</td>
</tr>
<tr>
<td>3:51 pm</td>
<td>Racial and Ethnic Equity in the Receipt of Medications for Opioid Use Disorder Following Emergency Department Visits for Opioid Overdose in the Medicaid Population</td>
<td>Thuy Nguyen, PhD; University of Michigan</td>
</tr>
<tr>
<td>4:08 pm</td>
<td>Development of a Statewide Office-Based Treatment Provider Network Expanding Access to Buprenorphine using the Successful Healthcare Improvement from Translating Evidence in Complex Systems Framework (SHIFT-Evidence)</td>
<td>Carma Deem Bolton, PhD; The University of Texas Health Science Center at San Antonio</td>
</tr>
<tr>
<td>4:25 pm</td>
<td>Beneficial Effects of Buprenorphine/Naloxone on Opioid Craving and Mental Health in Patients with Opioid Use Disorder</td>
<td>Li Li, MD; University of Alabama at Birmingham School of Medicine</td>
</tr>
</tbody>
</table>

### Session 1.4 • Overdose
**Room: Burnham**
**Moderator: Elizabeth A. Samuels, MD, MHS, MPH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Overdose Detection Technologies for People Who Use Alone</td>
<td>Ju Nyeong Park, MHS, PhD; Harm Reduction Innovation Lab, Brown University</td>
</tr>
<tr>
<td>3:17 pm</td>
<td>Prescription Opioid Receipt and Dose Change Prior to Fatal Opioid-Involved Overdose</td>
<td>Maryam Kazemitabar, PhD; Yale School of Medicine</td>
</tr>
<tr>
<td>3:34 pm</td>
<td>Opioid Overdose Risk Behaviors of Black Compared to White Overdose Survivors in San Francisco and Boston</td>
<td>Gabriela Reed, MD; Boston Medical Center</td>
</tr>
<tr>
<td>3:51 pm</td>
<td>System Dynamics Modeling to Inform Effective implementation of Evidence Based Practices to Prevent Opioid Overdose and Overdose Fatalities in New York State</td>
<td>Rachel L. Thompson, MSc; City University of New York Graduate School of Public Health &amp; Health Policy</td>
</tr>
<tr>
<td>4:08 pm</td>
<td>Characterizing Opioid Overdose Hotspots for Place-Based Overdose Prevention and Treatment Interventions: A Geo-Spatial Study</td>
<td>Elizabeth A. Samuels, MD, MHS, MPH; UCLA Department of Emergency Medicine</td>
</tr>
<tr>
<td>4:25 pm</td>
<td>Unintentional Drug Overdose Deaths Following Termination of Substance Use Disorder Treatment, New York City, 2016-2019</td>
<td>Chinazo Cunningham, MD, MS, Ashly E. Jordan, MPH, PhD; New York State Office of Addiction Services and Supports</td>
</tr>
</tbody>
</table>
### Session 1.5 • Homelessness and Criminal Justice

Room: Roosevelt & Cabin John  
Moderator: Phoebe A. Cushman, MD, MSc

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td><strong>Barriers and Facilitators to Outpatient-Based Opioid Treatment Retention among People Experiencing Homelessness</strong>&lt;br&gt;  Danielle R. Fine, MD, MSc; Harvard Medical School, Massachusetts General Hospital</td>
<td></td>
</tr>
<tr>
<td>3:17 pm</td>
<td><strong>Increasing Buprenorphine Access for Homeless-Experienced Populations</strong>&lt;br&gt;  Jacob D. Baylis, MPH; University of Utah</td>
<td></td>
</tr>
<tr>
<td>3:34 pm</td>
<td><strong>&quot;Holding Out&quot; in a Holding Cell: Clinical Case Demonstrates a Gap in Access to Medications for Opioid Use Disorder (MOUD)</strong>&lt;br&gt;  Phoebe A. Cushman, MD, MSc; Spectrum Health Systems, UMass Chan Medical School</td>
<td></td>
</tr>
<tr>
<td>3:51 pm</td>
<td><strong>Facing Mortality: Understanding Palliative and End-of-Life Care Needs for Patients with Medical Complexity and Substance Use Disorders</strong>&lt;br&gt;  Meg Devoe, MD; Oregon Health &amp; Science University</td>
<td></td>
</tr>
<tr>
<td>4:08 pm</td>
<td><strong>Medication for Opioid Use Disorders (MOUD) Providers’ Perspectives on Working with Drug Courts</strong>&lt;br&gt;  Ekaterina Pivovarova, PhD; University of Massachusetts Chan Medical School</td>
<td></td>
</tr>
<tr>
<td>4:25 pm</td>
<td><strong>Access to and Predictors of Substance Use Treatment Among People Who are Incarcerated</strong>&lt;br&gt;  Samuel Chen, MSc; The Pritzker School of Medicine at the University of Chicago</td>
<td></td>
</tr>
</tbody>
</table>

### Session 1.6 • Hospital-Based Care

Room: Arlington  
Moderator: Richard Bottner, DHA, PA-C, CPHQ, FACHE

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td><strong>Patients’ Experiences of New Addiction Consultation Service in New York City Public Hospitals</strong>&lt;br&gt;  Carla King, MPH; NYU Grossman School of Medicine</td>
<td></td>
</tr>
<tr>
<td>3:15 pm</td>
<td><strong>START: A Program to Initiate Substance Use Treatment During Hospitalization for Patients in Texas</strong>&lt;br&gt;  Alanna Boulton, MHS 1, Richard Bottner, DHA, PA-C, CPHQ, FACHE 2, John Austin Weems-Embers, MD 3, Nicholas J. Christian, MBA, MD 4; (1)Dell Medical School at The University of Texas at Austin, (2)Colorado Hospital Association, (3)Dell Medical School at the University of Texas at Austin, (4)Yale School of Medicine</td>
<td></td>
</tr>
<tr>
<td>3:30 pm</td>
<td><strong>&quot;One of the Most Complex Medical Problems We Treat in the Hospital&quot;: Hospital Clinician Perspectives on an Inpatient Addiction Consultation Team</strong>&lt;br&gt;  Madison Rodriguez, BS; University of California, San Francisco</td>
<td></td>
</tr>
<tr>
<td>3:45 pm</td>
<td><strong>Trends in Against Medical Advice Discharge and Associations with Inpatient Utilization for Patients with Opioid Use Disorder: A Nation-Wide Cohort Study</strong>&lt;br&gt;  Ashish P. Thakrar, MD; University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>4:00 pm</td>
<td><strong>Interprofessional Perspectives on Caring for Hospitalized Patients with Opioid Use Disorder</strong>&lt;br&gt;  Margaret Lowenstein, MD, MSHP; University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>4:15 pm</td>
<td><strong>Interprofessional Clinician Experiences Caring for Patients With Substance Use Disorders: A Needs Assessment</strong>&lt;br&gt;  M Holliday Davis 1,2, Margaret Lowenstein, MD, MSHP 3;(1)University of Pennsylvania Center for Addiction Medicine and Policy, (2)Sol Collective, (3)University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td><strong>Exploring Patient Perspectives on Care for Hospitalized People Who Use Drugs</strong>&lt;br&gt;  Margaret Lowenstein, MD, MSHP; University of Pennsylvania</td>
<td></td>
</tr>
</tbody>
</table>
Session 1.7 • Recovery Support and Community Engagement  
Room: Renwick & Bulfinch  
Moderator: Richard F. Hamner, LMSW

3:00 pm  Implementing and Evaluating Group Model Building as a Participatory Approach to Foster Community Dialogue and Systems Learning Around Connecticut’s Good Samaritan Laws  
Rachel L. Thompson, MSc; City University of New York Graduate School of Public Health & Health Policy

3:15 pm  A Community Peer Recovery Support Specialist Model for Engaging People Who Use Drugs in Rural Communities  
Philip Todd Korthuis, MD, MPH, Joanna Cooper, BS; Oregon Health & Science University

3:30 pm  Learning Collaboratives (LCs) in the HEALing Communities Study: A Community-Engaged Training and Technical Assistance (TTA) Approach in a Multi-Community Overdose Reduction Intervention  
Maria Rudorf, MA; Boston Medical Center

3:45 pm  How Do Peer Support Specialists Experience Transitions to Employment Following State Certification?  
Elizabeth Siantz, PhD; College of Social Work, University of Utah

4:00 pm  Adding Online Access to a Sober-Active Community, The Phoenix, Supports Recovery From Substance Use  
Bethany Collinson, PhD; The Phoenix

4:15 pm  Adapting an Evidence Supported Family-Oriented Treatment to Meet the Needs of Families With Caregiver Substance Misuse  
Kalyn Holmes, PhD Candidate; Denver Health Hospital Authority

4:30 pm  Increasing Access and Quality of Recovery Support Services Through a Statewide Network in Texas  
Richard F. Hamner, LMSW; University of Texas Health Science Center of San Antonio

Session 1.8 • Treatment Access and Pharmacists  
Room: Wilson  
Moderator: Kimber Richter, PhD, MPH

3:00 pm  RAMP-UP: Pharmacist-Led Rapid Access to Methadone Maintenance for Patients With Opioid Use Disorder at Penn Pilot  
Emily R. Casey, PharmD; The Hospital of the University of Pennsylvania

3:17 pm  Private Insurance Failure to Pay: A Major Barrier to Accessing Treatment for Substance Use Disorders  
Kimber Richter, PhD, MPH; University of Kansas Medical Center

3:34 pm  The Roles, Activities, and Opportunities of Clinical Pharmacists in a National Initiative to Improve Office-Based Buprenorphine Care  
Adam J. Gordon, MD; University of Utah School of Medicine

3:51 pm  Developing an Interactive Pharmacy Map of Buprenorphine Access Across Philadelphia  
Rachel French, PhD, RN; University of Pennsylvania

4:08 pm  Distance as a Barrier to Addiction, Mental Health and Primary Care for Persons with Recent Homeless Experience  
Stefan G. Kertesz, MD, MSc; Heersink UAB School of Medicine

4:25 pm  Telemedicine Treatment Retention Characteristics from REACH, a Low Barrier, Community-Based Buprenorphine Clinic in Upstate New York  
Judith Griffin, MD; The REACH Project, Inc.
Skills Based Workshops
Friday, November 3rd 3:15 pm-4:45 pm

Overcoming Pharmacy Barriers to Buprenorphine Access Through Education and Communication
Room: Burnham

Sorina Torrez, PharmD; Lucas Hill, PharmD, BCACP; Lindsey Loera, PharmD; Jennifer Bosworth, PharmD; Amber Tran, PharmD Candidate; Grace Ukazim, PharmD Candidate; The University of Texas at Austin, College of Pharmacy, PhARM Program, Austin, TX

“I’m So Glad You’re Here:” Harm Reduction Wound Care for Xylazine and Injection-Related Wounds in Low Barrier and Street Based Settings
Room: Arlington & Cabin John

Rachel McFadden, BSN, RN, Prevention Point Philadelphia, Philadelphia, PA; Ashish Thakrar, MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Rebecca Hosey, BSN, MPH, RN, Prevention Point Philadelphia, Philadelphia, PA; Rachel Neuschatz, MSN, RN, Philadelphia Department of Public Health, Philadelphia, PA; Raagini Jawa, FASAM, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA; Stephanie Klipp, CARN, Unity Recovery, Philadelphia, PA

Meeting 'em Where They’re at: Aligning Police and EMS Practices With Harm Reduction Goals Through Occupational Safety Training
Room: Declaration AB

Rachel Winograd, PhD, University of Missouri-Saint Louis, St. Louis, MO; Leo Beletsky, JD, Northeastern University, Boston, MA; Brad Ray, PhD, RTI International, NC; Liz Connors, LCSW, Missouri Institute of Mental Health, St. Louis, MO; Marc Doll, BA, Saint Charles Fire Department, St. Charles, MO; Joe Foege, CPS, Center for Life Solutions, Hazelwood, MO; Melody Quinn, MBA, St. Louis County Police Department, St Louis, MO

Public Engagement and Program-Building Under Conditions of Public Skepticism
Room: Constitution CDE

Leah Leisch, MD, Heersink UAB School of Medicine and Birmingham Alabama VA Healthcare System, Birmingham, AL; Davis Bradford, MD, University of Alabama at Birmingham School of Medicine, Birmingham, AL; Stefan Kertesz, MD, MSc, Heersink UAB School of Medicine, Birmingham, AL; Hannah Stone, MD, University of Alabama at Birmingham, Birmingham, AL
Leveraging Legal Protections to Counter Discrimination Against People Who Use(d) Drugs: The Essential Role of Healthcare Professionals

Room: Wilson & Roosevelt

Kate Boulton, MPH, JD, Vital Strategies, New York, NY; Derek Carr, JD, Vital Strategies, New York, NY; Diane Johnston, JD, Legal Action Center, New York, NY; Simeon Kimmel, MD, Chobanian and Avedisian Boston University School of Medicine; Boston Medical Center, Boston, MA

Applying Geriatric Principles to the Delivery of Equitable and Evidence-based Care to Patients with Substance Use Disorders and Multimorbidity

Room: Renwick & Bulfinch

Mim Ari, MD, University of Chicago, Chicago, IL; Kimberly Beiting, MD, Vanderbilt University Medical Center, Nashville, TN; Justina Groeger, MD, MPH, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY; Benjamin Han, MD, University of California San Diego, La Jolla, CA; A Landi, MD, University of Chicago Medicine & Biological Sciences, Chicago, IL; Ajay Manhapra, MD, Hampton VA Medical Center, Hampton, VA; Vassiliki Pravodelov, FACP, MD, Boston University Chobanian & Avedisian School of Medicine, Boston, MA

Optimizing Responses to Overamping: A Workshop to Build Capacity for The Identification and Response of Overamping for the SUD Treatment Provider

Room: Latrobe

Rachel Xue, BA, Justin Alves, RN, Marielle Baldwin, MD, MPH, Kristin Parent, Megan Hudson, RN; Boston Medical Center, Boston, MA; Thomasina Baker, Stimulant Treatment and Recovery Team (START), Boston, MA

Contingency Management 2.0: Novel Strategies for Implementing Contingency Management in Diverse Settings

Room: Penn AB

Amy Kennedy, MD, MS, Sara Chaudhry, ACSW, LICSW, Sergio Flores, PsyD, VA Puget Sound Healthcare System, Seattle, WA; Dominick DePhilippis, PhD, Department of Veterans Affairs, Galloway, NJ
**Session 2.1• Alcohol**  
**Room: Burnham**  
**Moderator: Bryant Shuey, MD, MPH**

2:00 pm  **High Test-Retest Reliability of the Alcohol Use Disorder Identification Test-Consumption Version (AUDIT-C) Completed by Primary Care Patients in Routine Care**  
Claire Simon, MD; University of Washington

2:17 pm  **Facilitators and Barriers of Alcohol-related Goals for Latinx Individuals Hospitalized with Alcohol Use Disorder**  
Mariam Carson, BS, MD Candidate, MSc; University of California, San Francisco

2:34 pm  **Pandemic-Related Changes in Alcohol-Related Adverse Events: A Times Series Analysis of Commercial Claims Data**  
Bryant Shuey, MD, MPH; Harvard Medical School

2:51 pm  **Latino-White Disparities in Screening and Receipt of Medications for Unhealthy Alcohol Use in the OCHIN Network of Community Health Centers**  
Brian Chan, MD; OCHIN Network

3:08 pm  **Are Electronic Brief Interventions for Unhealthy Alcohol Use Based on Norms and Risk Perception Working as Hypothesized?**  
Joseph Studer, PhD; Lausanne University Hospital and University of Lausanne

**Session 2.2• Women’s and Children’s Health**  
**Room: Latrobe**  
**Moderator: Sarah M. Bagley, MD**

2:00 pm  **The Influence of Targeted HIV Prevention Advertising on High-Risk Women Who Inject Drugs**  
Laura Starbird, MSN, PhD, RN; University of Pennsylvania School of Nursing

2:17 pm  **A Qualitative Exploration of the Perspectives of School-Based Health Center Staff About Providing Opioid Overdose Prevention Education and Treatment of Opioid Use Disorder**  
Sarah M. Bagley, MD; Boston Medical Center and Chobanian & Avedisian School of Medicine

2:34 pm  **Associations Between Individual and Hospital-Level Determinants in the Medical Diagnosing of Prenatal Substance Use and Referrals to Child Protection Systems: Multi-level Modeling of a California Birth Cohort**  
Julia Reddy, MA; Gillings School of Global Public Health, University of North Carolina - Chapel Hill

2:51 pm  **Associations of Postpartum Opioid Use Disorder Medication Treatment Outcomes With Neighborhood-Level Social Determinants of Health and Prenatal Treatment Receipt**  
Caitlin E. Martin, MD; Virginia Commonwealth University

3:08 pm  **County-Level Neonatal Opioid Withdrawal Syndrome Rates and Real-World Access to Buprenorphine in Pregnancy: an Audit (“Secret Shopper”) Study in Missouri**  
Kevin Y. Xu, MD, MPH; Washington University School of Medicine

3:25 pm  **The Pre-Dobbs Landscape of Contraception Access for Reproductive-Age People with Opioid Use Disorder in the United States**  
Kevin Y. Xu, MD, MPH; Washington University School of Medicine in St. Louis
### Session 2.3 • Education #2
**Room: Roosevelt & Cabin John**  
**Moderator: Emily Hurstak, MAS, MD, MPH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td><strong>TA Novel Adaptation of the Project ECHO Model to Convene Leaders in SUD Care</strong></td>
<td>Daniel B. Hoover, MD; Oregon Health &amp; Science University</td>
</tr>
<tr>
<td>2:17 pm</td>
<td><strong>Harm Reduction Training for First Year Medical Students to Decrease Stigma Towards People Who Inject Drugs</strong></td>
<td>Tucker Avra, BS, DVM, Amanda Cowan, Msc; David Geffen School of Medicine at UCLA, Community Health Project LA</td>
</tr>
<tr>
<td>2:34 pm</td>
<td><strong>Experiences of Underrepresented Groups in Addiction Medicine Training Programs: a Qualitative Interview Study</strong></td>
<td>Amanda Marie Fitzpatrick, MPH 1, Sophia M. Ly, Medical Student, MSc 1, Emily Hurstak, MAS, MD, MPH 2; (1)Boston Medical Center, (2)Boston Medical Center, Boston University School of Medicine</td>
</tr>
<tr>
<td>2:51 pm</td>
<td><strong>Characterizing Addiction Medicine Training in Canada: A Mixed Methods Study of Fellowship Program Directors</strong></td>
<td>Clara Lu, MD; McMaster University</td>
</tr>
<tr>
<td>3:08 pm</td>
<td><strong>Training Clinicians to Prescribe Buprenorphine for Opioid Use Disorder (OUD) in the Era of Changing Regulations</strong></td>
<td>Nikki Kalani Apana, BA, MD Candidate, Irina Kryzhanovskaya, MD; University of California, San Francisco</td>
</tr>
<tr>
<td>3:25 pm</td>
<td><strong>Medical Students’ Perceived Value of Buprenorphine Waiver Training After Removal of Training Requirement</strong></td>
<td>Jared Wilson Klein, MD, MPH; University of Washington; Harborview Medical Center</td>
</tr>
</tbody>
</table>

### Session 2.4 • MOUD #2
**Room: Constitution CDE**  
**Moderator: Megan E Buresh, MD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td><strong>Piloting a Hospital Rapid Methadone Induction Guideline in the Fentanyl Era</strong></td>
<td>Patricia Liu, MD; Oregon Health &amp; Science University</td>
</tr>
<tr>
<td>2:17 pm</td>
<td><strong>Clinicians’ Perceptions and Practices of Urine Drug Testing in Buprenorphine Treatment</strong></td>
<td>Isabel H Lamont, BA 1, Mariya Masyukova, MD, MSc 2; (1)Montefiore Hospital/ Albert Einstein College of Medicine, (2)Project Renewal, Inc.</td>
</tr>
<tr>
<td>2:34 pm</td>
<td><strong>Low Dose IV Buprenorphine Inductions for Patients with Opioid Use Disorder and Concurrent Pain: A Retrospective Case Series</strong></td>
<td>John P. Murray, MA, MD, Geoffrey Pucci, PharmD; University of Chicago</td>
</tr>
<tr>
<td>2:51 pm</td>
<td><strong>Rurality and Non-Prescribing Clinicians’ Treatment Orientations and Attitudes Toward Medications for Opioid Use Disorder</strong></td>
<td>Aaron R. Brown, LCSW, PhD; University of Kentucky</td>
</tr>
<tr>
<td>3:08 pm</td>
<td><strong>Outcomes of a Mobile Medical Unit for Low-Threshold Buprenorphine Access Targeting Opioid Overdose Hot Spots in Chicago</strong></td>
<td>Elisabeth A. Poorman, MD 1, Sarah Messmer, MD 2; (1)Jesse Brown VA, (2)University of Chicago-Illinois</td>
</tr>
<tr>
<td>3:25 pm</td>
<td><strong>Patient Perspectives on Transitioning from a Low-Threshold Buprenorphine Program to Clinic-Based Care</strong></td>
<td>Noelle G. Martinez, MD, MPH, Megan E Buresh, MD; Johns Hopkins School of Medicine</td>
</tr>
</tbody>
</table>
### Session 2.5 • ED-Based Care
**Room: Penn B**  
**Moderator: Gail D’Onofrio, MD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Low Incidence of Precipitated Withdrawal During a Multi-site ED Buprenorphine Clinical Trial in the Era of Fentanyl</td>
<td>Gail D’Onofrio, MD; Yale University School of Medicine</td>
</tr>
<tr>
<td>2:17 pm</td>
<td>Developing a Computable Phenotype to Identify Opioid Use Disorder in Emergency Department Visits</td>
<td>Erin Kim, MD Candidate; University of Michigan</td>
</tr>
<tr>
<td>2:34 pm</td>
<td>Prevalence of Fentanyl Analogues in Toxicology Profiles of Emergency Department Patients With Untreated Opioid Use Disorder</td>
<td>Ethan Cowan, MD; Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>2:51 pm</td>
<td>Buprenorphine Induction in Emergency Department Patients Following Reversal of Nonfatal Opioid Overdose With Naloxone</td>
<td>Samuel Chen, MSc; University of Chicago Pritzker School of Medicine</td>
</tr>
<tr>
<td>3:08 pm</td>
<td>Nationwide Capabilities Assessment of Emergency Department Care of Patients with Opioid Use Disorder: 2022 to 2023</td>
<td>Kathryn Hawk, MD, MHS; Yale University School of Medicine, Yale University</td>
</tr>
<tr>
<td>3:25 pm</td>
<td>The Incidence of Buprenorphine Precipitated Withdrawal in ED and Hospitalized Patients with Opioid Use Disorder and Fentanyl Use in Philadelphia: A Retrospective Cohort Study</td>
<td>Ashish P. Thakrar, MD; University of Pennsylvania Perelman School of Medicine</td>
</tr>
</tbody>
</table>

### Session 2.6 • Harm Reduction
**Room: Constitution A**  
**Moderator: Kathryn A. Dong, FASAM, MD, MSc**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Emergency Physician Perspectives on Harm Reduction and Supporting Patients Who Use Drugs</td>
<td>Kathryn A. Dong, FASAM, MD, MSc, Zoe KD Collins, BS; University of Alberta</td>
</tr>
<tr>
<td>2:17 pm</td>
<td>Association Between Low-Barrier Access to Methadone in an Outpatient Clinic via the “72 Hour Rule” and Emergency Department Utilization</td>
<td>Paul J. Christine, MD, PhD; Boston Medical Center</td>
</tr>
<tr>
<td>2:34 pm</td>
<td>Development of Scales to Measure the Acceptance of Harm Reduction</td>
<td>Zach Budesa, PhD; Missouri Institute of Mental Health</td>
</tr>
<tr>
<td>2:51 pm</td>
<td>Exploring Drug Checking Services for People Who Use Drugs and Harm Reduction Staff: Pre-Implementation Study</td>
<td>Whitney A. Ludwig, MPH; University of Michigan School of Nursing</td>
</tr>
<tr>
<td>3:08 pm</td>
<td>Implementing Harm Reduction Vending Machines in a California Veterans Affairs Syringe Services Program</td>
<td>Tessa Lynne Rife-Pennington, PharmD, BCGP; University of California, San Francisco, School of Pharmacy</td>
</tr>
<tr>
<td>3:25 pm</td>
<td>&quot;You Got to do it Right&quot;: Patient and Staff Perspectives on Best Practices for Hospital-Based Harm Reduction</td>
<td>Leah Fraimow-Wong, BA; University of California, San Francisco</td>
</tr>
</tbody>
</table>
### Session 2.7 • Post-Overdose
**Room: Penn A**  
**Moderator: Leslie W. Suen, MD, MAS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Post-Overdose Outreach Programs in Massachusetts Since the Onset of COVID-19</td>
<td>Alexander Y. Walley, MD, MSC; Boston Medical Center</td>
</tr>
<tr>
<td>2:17 pm</td>
<td>The Impact of SHIELD Training on First Responders’ Harm Reduction Attitudes, Beliefs, and Knowledge</td>
<td>Saad T. Siddiqui, MPH; Missouri Institute of Mental Health</td>
</tr>
<tr>
<td>2:34 pm</td>
<td>Identifying Unintentional Fentanyl Exposure Among People Who Have Experienced an Opioid Overdose: A Quality Improvement Investigation from San Francisco Street Overdose Response Team</td>
<td>Patrick Low, Medical Student; University of California, San Francisco</td>
</tr>
<tr>
<td>2:51 pm</td>
<td>Applying a Naloxone Saturation Model in Missouri: Comparing Predictions to Reality</td>
<td>Rithvik Kondai, BA; Missouri Institute of Mental Health</td>
</tr>
<tr>
<td>3:08 pm</td>
<td>The Intersections of Mental Health with Substance Use and Related Barriers to Treatment Among Opioid Overdose Survivors in Boston, MA</td>
<td>Ranjani K. Paradise, PhD; Institute for Community Health</td>
</tr>
<tr>
<td>3:25 pm</td>
<td>Evaluating Oxygen Monitoring and Administration during Overdose Responses at a Sanctioned Overdose Prevention Site in San Francisco, California: A Mixed-Methods Study</td>
<td>Leslie W. Suen, MD, MAS; University of California, San Francisco at Zuckerberg San Francisco General Hospital</td>
</tr>
</tbody>
</table>

### Session 2.8 • Primary Care
**Room: Wilson**  
**Moderator: Michael Incze, MD, MEd**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>&quot;It’s Like a Partnership&quot;: Exploring the Primary Care Experiences and Self-Defined Primary Care Goals of People Who Use Drugs</td>
<td>Katherine Dunham, MPH; Yale School of Public Health</td>
</tr>
<tr>
<td>2:17 pm</td>
<td>Co-Location of Medical and Psychiatric Care in an Opioid Treatment Program Associated With a Dramatic Decrease in Acute Care Utilization</td>
<td>Aaron D. Greenblatt, MD; University of Maryland School of Medicine</td>
</tr>
<tr>
<td>2:34 pm</td>
<td>15-Month Outcomes of a Primary Care-Based Transition Clinic for Patients Newly Initiating Buprenorphine for Opioid Use Disorder</td>
<td>Michael Incze, MD, MEd; University of Utah</td>
</tr>
<tr>
<td>2:51 pm</td>
<td>Treatment Outcomes of Patients on Long-Acting Injectable Buprenorphine in an Office-Based Addiction Treatment Setting Utilizing the Nurse Care Manager Model: A Retrospective Chart Review</td>
<td>Annie Potter, CARN-AP, MPH, MSN, NP; Boston Medical Center, Boston University Chobanian &amp; Avedisian School of Medicine, Grayken Center for Addiction</td>
</tr>
<tr>
<td>3:08 pm</td>
<td>Improving Care for Persons with Homeless Experience and Opioid Use Disorder within an Interdisciplinary Primary Care Clinic</td>
<td>Audrey L. Jones, PhD; University of Utah - VA Salt Lake City Health Care System</td>
</tr>
<tr>
<td>3:25 pm</td>
<td>Qualitative Study of Early OUD Treatment Dropout in Primary Care</td>
<td>Rebecca Arden Harris, MD, MSc; Perelman School of Medicine, University of Pennsylvania</td>
</tr>
</tbody>
</table>
Session 2.10 • Stimulants, Chronic Pain, Suicide, Spirituality, and Abstinence
Room: Arlington
Moderator: Corinne A. Beaugard, MSW

2:00 pm  
**Trends in Emergency Department Visits Associated With Stimulant Use Among Adults in California, 2016-2021**  
Wayne Kepner, MPH 1,2, Benjamin H Han, MD 1;  (1)University of California San Diego, (2)San Diego State University

2:17 pm  
**Prevalence and Correlates of Suicide Attempts in a Sample of Residential OUD Patients: Data from Electronic Health Records**  
Julia Marie Thomas, BS; Maryland Treatment Centers Inc.

2:34 pm  
**Baseline Substance Use Patterns of Zambian Adolescents Participating in a Spiritually-Based Resilience Training Program for Substance Use Prevention/Intervention**  
Sion Kim Harris, PhD, RN; Center for Adolescent Behavioral Health Research, Boston Children’s Hospital, Harvard Medical School

2:51 pm  
**Abstinent and Non-Abstinent Substance Users Who Resolved an Addiction: A mixed Methods Analysis**  
Corinne A. Beaugard, MSW; Boston University

3:08 pm  
**Medical Cannabis and Opioid Use Among Adults with Chronic Pain: Preliminary Results From an 18-month Longitudinal Study**  
Deepika E. Slawek, MD, MPH, MSc; Montefiore Medical Center/Albert Einstein College of Medicine

3:25 pm  
**Patient Perspectives on Stimulant Use Disorder Treatment With Contingency Management and Community Reinforcement Approach in Permanent Supportive Housing**  
Sarah Leyde, MD 1, Claire Simon, MD 1, Amy J. Kennedy, MD, MS 2;  (1)University of Washington, (2) VA Puget Sound Healthcare System
Founded in 1976, AMERSA is the only national non-profit organization focused on multidisciplinary health professionals who work everyday to improve outcomes for people with substance use disorders. AMERSA’s mission is to improve health and well-being through interdisciplinary leadership and advocacy in substance use education, research, clinical care, and policy.
Funding for this conference was made possible (in part) by 2R13 DA015046-22 from the National Institute on Drug Abuse (NIDA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.